<DOC>
	<DOC>NCT03071133</DOC>
	<brief_summary>An observational, postmarketing commitment following the marketing authorization for DCV Trio therapy in Japan.</brief_summary>
	<brief_title>Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Patients who are initiating the treatment with DCV Trio therapy under the approved indications, dosage, and administration Patients who use the DCV Trio off label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>